Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 38,843 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the completion of the sale, the chief executive officer now owns 180,683 shares of the company's stock, valued at $5,718,616.95. This trade represents a 17.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ionis Pharmaceuticals Stock Performance
NASDAQ IONS traded up $0.01 during trading hours on Monday, reaching $31.41. 386,825 shares of the company were exchanged, compared to its average volume of 1,576,330. Ionis Pharmaceuticals, Inc. has a 1 year low of $31.03 and a 1 year high of $52.34. The business's 50 day simple moving average is $34.79 and its 200-day simple moving average is $39.50. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $4.96 billion, a P/E ratio of -12.86 and a beta of 0.34.
Analysts Set New Price Targets
Several analysts have weighed in on IONS shares. StockNews.com cut shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Piper Sandler dropped their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Wells Fargo & Company cut their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a report on Thursday, November 7th. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.65.
Read Our Latest Analysis on Ionis Pharmaceuticals
Hedge Funds Weigh In On Ionis Pharmaceuticals
Several large investors have recently modified their holdings of the business. Nicollet Investment Management Inc. increased its stake in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock worth $817,000 after purchasing an additional 294 shares in the last quarter. Amalgamated Bank increased its stake in shares of Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after purchasing an additional 300 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after purchasing an additional 303 shares in the last quarter. Itau Unibanco Holding S.A. increased its stake in shares of Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock worth $43,000 after purchasing an additional 314 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of Ionis Pharmaceuticals by 2.1% in the third quarter. Bleakley Financial Group LLC now owns 16,678 shares of the company's stock worth $668,000 after purchasing an additional 338 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Further Reading
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
